Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ENTA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Sales Growth
YoY
Current
Estimates
Return on Equity
QoQ
Institutionnal Ownership
QoQ
Q1.23
N/A
-1.79
vs -1.63
Q2.23
N/A
-1.86
vs -1.53
Q3.23
N/A
-1.33
vs -1.27
Q4.23
N/A
-1.58
vs -1.39
Q1.24
N/A
-1.47
vs -1.79
Q2.24
N/A
-1.07
vs -1.86
Q3.24
N/A
-1.36
vs -1.33
Q4.24
N/A
-1.05
vs -1.58
Q1.25
N/A
-1.15
vs -1.47
Q2.25
N/A
-1.23
vs -1.07
Q1.23
-5%
17.8M vs 18.7M
Q2.23
-3%
18.9M vs 19.5M
Q3.23
-7%
18.9M vs 20.3M
Q4.23
-24%
18M vs 23.6M
Q1.24
-4%
17.1M vs 17.8M
Q2.24
-5%
18M vs 18.9M
Q3.24
-23%
14.6M vs 18.9M
Q4.24
-6%
17M vs 18M
Q1.25
-6%
16M vs 17.1M
Q2.25
-14%
15.5M vs 18M
Q1.23
-14%
-0.14
vs -0.10
Q2.23
-16%
-0.16
vs -0.14
Q3.23
-13%
-0.13
vs -0.16
Q4.23
-17%
-0.17
vs -0.13
Q1.24
-19%
-0.19
vs -0.17
Q2.24
-15%
-0.15
vs -0.19
Q3.24
-22%
-0.22
vs -0.15
Q4.24
-20%
-0.20
vs -0.22
Q1.23
147
147
vs 150
-2%
Q2.23
134
134
vs 147
-9%
Q3.23
132
132
vs 134
-1%
Q4.23
106
106
vs 132
-20%
Q1.24
108
108
vs 106
2%
Q2.24
101
101
vs 108
-6%
Q3.24
111
111
vs 101
10%
Q4.24
107
107
vs 111
-4%
businesswire.com
7 hours ago
businesswire.com
7 hours ago
zacks.com
10 hours ago
zacks.com
13 hours ago
businesswire.com
16 hours ago
zacks.com
18 hours ago
Forecast
270%2025-Revenue
-330%2025-EPS
-173%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Evercore ISI
upgradePrevious: Not converted
2022-07-06
Now: Outperform
Quote Panel
Key Metrics
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.26 ( 5.14%)
Relative Strenght
21
Volume Buzz
-63%
Earning Acce
No
Dist 52w H.
69%Relative Strength
ENTA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|